-- World Leader in Fibroblast Technology Advances Intellectual Property
     Position with their 250th Patent Filed Today

FibroGenesis, a Texas-based regenerative medicine company focused on tissue 
regeneration and chronic disease reversal using Human Dermal Fibroblasts 
(HDFs), today announced the filing of its 250th patent related to its 
fibroblast cell therapy platform.

Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg  

Extending its world leading position as the authority on using fibroblasts to 
treat chronic diseases, FibroGenesis expands its worldwide intellectual 
property portfolio covering diseases such as COVID-19 ARDS, Degenerative Disc 
Disease, Multiple Sclerosis, Parkinson's, Diabetes, Cancer, Chronic Traumatic 
Encephalopathy (CTE), Pain and Muscular Dystrophy.

"Our scientific team is creating new opportunities for this "super cell," 
commented Tom Ichim, Ph.D., Chief Scientific Officer of FibroGenesis.  
"Internal data and emerging third party validation, shows our proprietary 
universal donor fibroblast-based product outperforms existing approaches.  Our 
broad intellectual property establishes FibroGenesis as the gatekeeper for 
anyone entering this space."

"As we continue to organically expand our intellectual property portfolio, we 
are humbled by the equally expanding clinical capabilities of this unique cell 
source," said Pete O'Heeron, Chief Executive Officer, FibroGenesis.  "Our new 
clinical programs are providing evidence of a cell source superior to stem 
cells and our proprietary position gives us the protection to continue our 
growth."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company 
developing an innovative solution for chronic disease treatment using human 
dermal fibroblasts. Currently, FibroGenesis holds 250 U.S. and international 
issued patents/patents pending across a variety of clinical pathways, including 
Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic 
Encephalopathy, Cancer, Diabetes, Liver Failure and Heart Failure. Funded 
entirely by angel investors, FibroGenesis represents the next generation of 
medical advancement in cell therapy. 

Visit www.Fibro-Genesis.com.

SOURCE: FibroGenesis

CONTACT: info@fibro-genesis.com